van Hulst, Marinus <br/><br/>
The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands.  [electronic resource] 

 -  Journal of medical economics  Jan 2018 
 - 38-46 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.1080/13696998.2017.1372222  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antithrombins--economics<br/>Atrial Fibrillation--complications<br/>Cohort Studies<br/>Cost-Benefit Analysis--economics<br/>Dabigatran--economics<br/>Female<br/>Humans<br/>Male<br/>Markov Chains<br/>Netherlands<br/>Quality-Adjusted Life Years<br/>Retrospective Studies<br/>Risk Assessment<br/>Thromboembolism--etiology<br/>Treatment Outcome<br/>Vitamin K--administration & dosage